Human Serum Albumin (HSA) Nanoparticles as Drug Delivery System: Preparation, Optimization and Characterization Study (original) (raw)
Related papers
African Journal of …, 2010
The objective of the present study was to optimize the fabrication of bovine serum albumin (BSA) nanoparticle by applying the Taguchi method with characterization of the nanoparticle bioproducts. BSA nanoparticles have been extensively studied in our previous works as suitable carrier for drug delivery, since they are biodegradable, non-toxic and non antigenic. A statistical experimental design method (Taguchi method with L16 orthogonal array robust design) was implemented to optimize experimental conditions of the purpose. Agitation speed, initial BSA concentration, pH and temperature were considered as process parameters to be optimized. As the result of Taguchi analysis in this study, temperature and agitation speed were the most influencing parameters on the particle size. The minimum size of nanoparticles (~74 nm) were obtained at 4°C, pH 7.5, 15 mg ml -1 BSA concentration and agitation speed of 500 rpm. As for characterization of the products, Atomic Force microscopy (AFM), Scanning Electron microscopy (SEM) and Sodium Dodecyl Sulphate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) as well as Fourier Transform Infra-Red (FTIR) techniques were employed.
Enzymatic degradation of bovine serum albumin nanoparticles for drug delivery
2010
Coacervation is a mild process for developing protein NPs. Bovine serum albumin (BSA) NPs formed via this technique were stabilized using poly-L-Lysine (PLL); short interfering ribonucleic acid (siRNA) was used as a model drug for encapsulation. Specific and non-specific degradation of these coated and uncoated BSA NPs were carried using matrix metalloproteinase-2 (MMP-2) and trypsin, respectively. The particles were characterized with atomic force microscopy, zetapotential, and photon correlation spectroscopy measurements. There was a significant increase in the zeta potential of BSA NPs upon coating. Trypsin digested the uncoated and coated BSA NPs and resulted in higher BSA release from the particles. However, MMP-2 treatment did not result in higher release of BSA from coated NPs despite the cleavability of coated polymer by MMP-2. This study described a method for obtaining BSA NPs in a controllable size range. Such particles showed degradability in the presence of trypsin and could be promising for targeted drug delivery applications. I would like to thank my lovely wife for her understanding and patience; her help in thesis writing was invaluable. My sincere thank to the lab members especially Guilin Wang and summer student, Haran Yogasundaram for their contributions in this project. Lastly, I would like to express gratitude to my parents to support me throughout my life in all my decisions.
Protein Based Nanostructures for Drug Delivery
Journal of Pharmaceutics, 2018
The key role of protein based nanostructures has recently revolutionized the nanomedicine era. Protein nanoparticles have turned out to be the major grounds for the transformation of different properties of many conventional materials by virtue of their size and greater surface area which instigates them to be more reactive to some other molecules. Protein nanoparticles have better biocompatibilities and biodegradability and also have the possibilities for surface modifications. These nanostructures can be synthesized by using protein like albumin, gelatin, whey protein, gliadin, legumin, elastin, zein, soy protein, and milk protein. The techniques for their fabrication include emulsification, desolvation, complex coacervation, and electrospray. The characterization parameters of protein nanoparticles comprise particle size, particle morphology, surface charge, drug loading, determination of drug entrapment, and particle structure and in vitro drug release. A plethora of protein nan...
Applied Surface Science, 2015
The protein nanoparticles formulation is a challenging task as they are prone to undergo conformational transitions while processing which may affect bioavailability for bioactive compounds. Herein, a modified desolvation method is employed to prepare Bovine Serum Albumin nanoparticles, with controllable particle size ranging from 100 to 300 nm and low polydispersity index. The factors influencing the size and structure of BSA NPs viz. protein concentration, pH and the conditions for purification are well investigated. The structure of BSA NPs is altered due to processing, and may affect the effective binding ability with drugs and bioactive compounds. With that aims, investigations of molecular characteristics of BSA NPs are carried out in detail by using spectroscopic techniques. UV-visible absorption and Fourier Transform Infrared demonstrate the alteration in protein structure of BSA NPs whereas the FT-Raman spectroscopy investigates changes in the secondary and tertiary structures of the protein. The conformational changes of BSA NPs are observed by change in fluorescence intensity and emission maximum wavelength of tryptophan residue by fluorescence spectroscopy. The field emission scanning electron and atomic force microscopy micrographs confirm the size and semi-spherical morphology of the BSA NPs. The effect of concentration and pH on particle size distribution is studied by particle size analyzer.
Production of biological nanoparticles from bovine serum albumin for drug delivery
African Journal of …, 2010
Bovine serum albumin (BSA) was used for generation of nanoparticles in a drug delivery system. The size of the fabricated nano-particles was measure by laser light scanning. Several process parameters were examined to achieve a suitable size of nanoparticle such as pH, temperature, BSA concentration, agitation speed, glutaraldehyde concentration, organic solvent adding rate and the ratio of BSA/organic solvent. The smallest size of nanoparticles achieved, was 101 nm and the largest size was 503 nm. The most effective parameters for the fabrication of the nanoparticles were the agitation speed and the media temperature. The minimum size of nanoparticles at the desired incubator of 4°C and constant agitation rate of 300-400 rpm was obtained. The impact of protein concentration and additional rate of organic solvent (i.e. ethanol) upon the particle size was investigated. The protein concentration of 5-40 mg.ml-1 was resulted; the main effect on the particle size and minimum mean size diameter gained was 30 mg.ml-1 protein concentration. The nanoparticle sample was purified with 50,000 g centrifuge then followed by dialysis, micro and ultrafiltration and then analyzed by SEM, PCS as well as SDS gel electrophoresis.
Protein-based nanoparticles for drug delivery purposes
International Journal of Pharmaceutics, 2020
Proteins represent a group of biopolymers with interesting properties to be employed as raw materials in the preparation of nanoparticles for drug delivery purposes. Due to the inherent properties of proteins (i.e., biodegradability, amphiphilic properties, etc.) the resulting nanoparticles can be considered as versatility platforms for a variety of applications. Moreover, some proteins possess a GRAS (Generally Recognized as Safe) status or are considered as excipients by different Regulatory Agencies. As result of this, the resulting nanoparticles and potential translation to clinic would be facilitated, compared to other materials (i.e., polymers). This review is focused on the main proteins employed in the preparation of nanoparticles as well as the procedures permitting their transformation into nanoparticles able of accommodating a high variety of bioactive compounds and drugs. Moreover, the review also provides examples of application of nanoparticles prepared from albumins, globulins, prolamins or macromolecules derived from proteins.
Approaches and Role of Protein Based Nanoparticles in Drug Delivery System: A Review
Indian Research Journal of Pharmacy and Science, 2019
Protein based nanoparticles are investigated size, container-like shape, natural source, biocompatibility, and biodegradability. range in size from about 1-1000 nanometers in diameter, about one thousand in a human body. These are made up by a variety of materials including metals, polysaccharides, and proteins which having biodegradability, bioavailability, and relatively low cost in nature. protein nanoparticles are e to process and can be modified by desired flexible fabrication, and high surface Nanoparticles can be made from a var Biological protein-based nanoparticles such as silk, keratin, collagen, elastin, corn zein, and soy protein nanoparticles are advantageous in having biodegradability, bioavailability, of protein based nanoparticles has recently use protein like albumin, gelatine. The techniques for their fabrication include emulsification, de coacervation, and electro-spray. The administration are explored and reported by the protein nanoparticles as drug delivery carriers.
Preparation of human serum albumin nanoparticles using a chemometric technique
Human serum albumin (HSA), a versatile protein carrier for drug delivery, is an ideal material to fabricate nanoparticles for drug delivery systems. These nanoparticles can accumulate in tumor interstitium due to the enhanced permeability and retention effect. The most important characteristics of HSA nanoparticles are particle size, shape, and zeta potential. A chemometric approach was applied for HSA nanoparticles' size optimization in this study. The effects of three experimental parameters; pressure (P) or power, organic solvent volume (V), and time (T), were investigated under sonication and high-pressure homogenization, using multivariate analysis. The trials were performed based on the Box-Behnken experimental design. The criteria for the appraisal of the descriptive ability of a multinomial were R 2 = 0.819, standard error = 20.420, and F-ratio = 19.550. The method was optimized with respect to the nanoparticles' size as a response. The Box-Behnken experimental design was applied to optimize and trial the robustness of the HSA nanoparticle preparation method.
Biopolymeric nanoparticles for oral protein delivery: Design and in vitro evaluation
Journal of Nanomedicine and Nanotechnology, 2011
Chitosan (CS) nanoparticles for the oral delivery of the protein, Human Serum Albumin (HSA) were prepared by two techniques (precipitation and ionic gelation) together with two anions (sodium sulfate or tripolyphosphate, TPP). HSA was loaded with CS nanoparticles by adsorption or entrapment loading protocols. The highest HSA association efficiency (93.43%) and loading capacity (58.65%) were obtained using ionic gelation technique with 0.1% w/v TPP as a crosslinker. The particle size of CS-HSA nanoparticles ranged between 100-320 nm with a high specific surface area (703-903 m 2 /g) and porosity (1060.99-1350.95 e-3 ml/g). Incubation of nanoparticles with lysozyme led to a reduction of 243 nm in particle size within 3 h. CS nanoparticles was redispersible after one month storage. CS/TPP nanoparticles prepared by precipitation/protein entrapment technique slowly released 10.34% HSA over 5 days which is suitable for vaccine or protein delivery while 86.54% of HSA was released from nanoparticles prepared by precipitation/ protein adsorption technique after 8 hr which is suitable for rapid drug release. Using ionic gelation technique, CS/ TPP nanoparticles released 22.47-38.65 % HSA over 5 days at 7:1 to 3:1 CS/TPP mass ratio, respectively. Both techniques retained the structural integrity of HSA after preparation and release processes which was proven via gel electrophoresis. Journal of Nanomedicine & Nanotechnology J o u rna l of N a n o m ed icine & N a n o te chnolo g y